ESG

The premier investor summit returns with a global tour, new sessions on real estate, and a renewed focus on funding critical pediatric cancer research.

Formerly Nature Wood Group, the forestry firm reports a surprise profit despite falling revenue after a complete change in ownership and leadership.

In a landmark decision, Jack Daniel's rare 14-year-old whiskey beat elite rivals in a blind tasting to claim the top honor from influential Bourbon Podcast.

Europi Property Group and Incus Capital launch a major joint venture to expand Ecologis, aiming to invest €100M in sustainable logistics across Iberia.

A new AI-operated system called Beacon promises to transform chronic pain care by unifying patient data and easing the administrative burden on clinics.

A CETY affiliate moves its 2.2 MW Vermont plant through regulatory hurdles, but past setbacks, new technology, and financial questions loom large.

Capital Clean Energy Carriers Corp. orders three advanced LNG carriers, positioning itself to capitalize on a projected surge in global gas demand.

With a new HQ and $2M in contracts, Taoping is leveraging AI and government policy to modernize China's aging elevators, but faces investor scrutiny.

Ultragenyx's stock plummets after its Osteogenesis Imperfecta drug fails to reduce fractures, a major blow for patients and a test of the firm's pipeline.

INOVIO's promising non-surgical treatment for a rare disease faces FDA scrutiny, casting doubt on its fast-track approval and impacting patient hopes.

With a new CEO and a booming market, mobile care provider instED is poised for major expansion. Here's what the move means for the future of healthcare.

Alico pivots from its 125-year citrus legacy to land development, and its CEO is set to face investors with a bold new plan for its 50,000 acres.

A new AI assistant is being piloted in the UAE, promising to cut doctor paperwork by 50% and give patients more face-to-face attention.

Cleveland expands its AI security robot program, citing reduced crime. But as other cities watch, questions of cost, privacy, and effectiveness emerge.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

The cleantech firm hits key milestones in German and Italian energy projects while its unconventional portfolio expands into biotech and agritech.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

Early data shows QurAlis' QRL-101 successfully engaged its intended target in ALS patients, a key step for a novel drug aimed at quelling neuronal storm.

Indonesia's Mowilex marks seven years of verified carbon neutrality, pivoting from certificates to permanent infrastructure with major solar power investments.